Zymeworks
Business Services · Canada · 201-500 Employees
View Company Info for Free
Overview
Headquarters
114 4th Ave E Suite 800, Vancouver, Brit...Phone Number
(604) 678-1388Website
www.zymeworks.comRevenue
$37.1 MillionStock Symbol
ZYMEIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Zymeworks
Zymeworks Inc. is a global biotechnology company focused on developing, managing, and commercializing innovative biotherapeutics for the treatment of cancer, autoimmune disorders, and other serious diseases with significant unmet medical needs. The company combines proprietary antibody engineering technologies with a strategic healthcare asset management approach to create long-term value through the discovery of novel therapeutics and the optimization of licensed healthcare assets.Explore more
Zymeworks Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Zymeworks your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Zymeworks
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Zymeworks recently announced quarterly report
Funding: Get notified immidiatlly once Zymeworks has new funding data
Product Launch: Get notified when Zymeworks launches new products
Zymeworks, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Click to see if Zymeworks had a recent Job posting/layoffs
Check out if Zymeworks is spiking on competitors!
Check if Zymeworks has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Zymeworks
Compare insights from companies similar to Zymeworks, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Zymeworks is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Zymeworks is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Zymeworks.
Zymeworks financials insights
Gather financial insights about Zymeworks, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Multiple Rounds
$22.3M
2015
Multiple Rounds
$34.4M
2016
Series A
$61.5M
2017
Stock Offering
$63.6M
2018
Stock Offering
$97.8M
2019
Stock Offering
$201.3M
2020
Stock Offering
$320.8M
Zymeworks Tech Stack
A closer look at the technologies used by Zymeworks
See more technologies
Most Recent Scoops
Person-Based
Earnings, Finance
Person-Based
Earnings, Finance
Person-Based
Earnings, Acquisitions, Finance
Person-Based
Earnings, Acquisitions, Finance
Person-Based
Medical Research, Pharmaceuticals
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Zymeworks
Sign Up For FreeTo access detailed company insights
Zymeworks Inc. is a global biotechnology company focused on developing, managing, and commercializing innovative biotherapeutics for the treatment of cancer, autoimmune disorders, and other serious diseases with significant unmet medical needs. The company combines proprietary antibody engineering technologies with a strategic healthcare asset mana... Read More
